Published in Pharmacol Ther on November 01, 2013
A Novel, Orally Bioavailable Nociceptin Receptor Antagonist, LY2940094, Reduces Ethanol Self-Administration and Ethanol Seeking in Animal Models. Alcohol Clin Exp Res (2016) 1.42
Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility. J Med Chem (2016) 1.10
Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems. Pharmacol Rev (2016) 1.02
A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies. Neuropsychopharmacology (2015) 0.87
Nociceptin/orphanin FQ peptide receptor antagonist JTC-801 reverses pain and anxiety symptoms in a rat model of post-traumatic stress disorder. Br J Pharmacol (2014) 0.81
A key role for the N/OFQ-NOP receptor system in modulating nicotine taking in a model of nicotine and alcohol co-administration. Sci Rep (2016) 0.79
Endocannabinoid Regulation of Reward and Reinforcement through Interaction with Dopamine and Endogenous Opioid Signaling. Neuropsychopharmacology (2017) 0.78
Knock-In Mice with NOP-eGFP Receptors Identify Receptor Cellular and Regional Localization. J Neurosci (2015) 0.78
A Genetic Animal Model of Alcoholism for Screening Medications to Treat Addiction. Int Rev Neurobiol (2016) 0.77
The affective dimension of pain as a risk factor for drug and alcohol addiction. Alcohol (2015) 0.77
Effects of the NOP agonist SCH221510 on producing and attenuating reinforcing effects as measured by drug self-administration in rats. Eur J Pharmacol (2014) 0.77
Nociceptin receptor activation does not alter acquisition, expression, extinction and reinstatement of conditioned cocaine preference in mice. Brain Res (2015) 0.77
Antidepressant activity of nociceptin/orphanin FQ receptor antagonists in the mouse learned helplessness. Psychopharmacology (Berl) (2016) 0.76
Antidepressant-like Effects of Buprenorphine are Mediated by Kappa Opioid Receptors. Neuropsychopharmacology (2016) 0.75
Parsing the hedonic and motivational influences of nociceptin on feeding using licking microstructure analysis in mice. Behav Pharmacol (2016) 0.75
Genetic Deletion of the Nociceptin/Orphanin FQ Receptor in the Rat Confers Resilience to the Development of Drug Addiction. Neuropsychopharmacology (2016) 0.75
Preclinical findings predicting efficacy and side-effect profile of LY2940094, an antagonist of nociceptin receptors. Pharmacol Res Perspect (2016) 0.75
Emerging targets for addiction neuropharmacology: From mechanisms to therapeutics. Prog Brain Res (2015) 0.75
Nociceptin receptor antagonist SB 612111 decreases high fat diet binge eating. Behav Brain Res (2016) 0.75
Decreased expression of nociceptin/orphanin FQ in the dorsal anterior cingulate cortex of suicides. Eur Neuropsychopharmacol (2015) 0.75
Social defeat disrupts reward learning and potentiates striatal nociceptin/orphanin FQ mRNA in rats. Psychopharmacology (Berl) (2017) 0.75
In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations. Eur J Pharmacol (2016) 0.75
Nociceptin/orphanin FQ induces simultaneously anxiolytic and amnesic effects in the mouse elevated T-maze task. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.75
The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev (1993) 19.60
Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature (1995) 6.72
Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science (1995) 5.74
Neurocircuitry of stress: central control of the hypothalamo-pituitary-adrenocortical axis. Trends Neurosci (1997) 5.41
Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci (1992) 5.27
Brain dopamine and reward. Annu Rev Psychol (1989) 4.41
Reward system and addiction: what dopamine does and doesn't do. Curr Opin Pharmacol (2006) 2.35
Endogenous opioid systems and alcohol addiction. Psychopharmacology (Berl) (1997) 2.11
Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther (2001) 2.00
The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential. Nat Rev Drug Discov (2008) 1.85
Theoretical frameworks and mechanistic aspects of alcohol addiction: alcohol addiction as a reward deficit disorder. Curr Top Behav Neurosci (2013) 1.80
Localization of orphanin FQ (nociceptin) peptide and messenger RNA in the central nervous system of the rat. J Comp Neurol (1999) 1.77
Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress. Proc Natl Acad Sci U S A (1997) 1.62
Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci (2003) 1.59
A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat. Proc Natl Acad Sci U S A (2000) 1.57
The mechanistic classification of addictive drugs. PLoS Med (2006) 1.54
Opioid receptor-like (ORL1) receptor distribution in the rat central nervous system: comparison of ORL1 receptor mRNA expression with (125)I-[(14)Tyr]-orphanin FQ binding. J Comp Neurol (1999) 1.52
Maintenance drugs to treat opioid dependence. BMJ (2012) 1.51
Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther (2004) 1.46
Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother (2009) 1.45
Nociceptin prevents stress-induced ethanol- but not cocaine-seeking behavior in rats. Neuroreport (2000) 1.43
Molecular cloning of a novel G protein-coupled receptor related to the opiate receptor family. J Neurochem (1995) 1.40
Increase by the ORL1 receptor (opioid receptor-like1) ligand, nociceptin, of inwardly rectifying K conductance in dorsal raphe nucleus neurones. Br J Pharmacol (1996) 1.40
Buprenorphine treatment of refractory depression. J Clin Psychopharmacol (1995) 1.37
Orphanin FQ/nociceptin: a role in pain and analgesia, but so much more. Trends Neurosci (1998) 1.34
Orphanin FQ/nociceptin blocks acquisition of morphine place preference. Brain Res (1999) 1.32
Nocistatin, a peptide that blocks nociceptin action in pain transmission. Nature (1998) 1.31
Unlimited access to heroin self-administration: independent motivational markers of opiate dependence. Neuropsychopharmacology (2006) 1.29
Responses of hypothalamic and pituitary mRNA to physical and psychological stress in the rat. J Endocrinol (1989) 1.27
Acquisition, expression, and reinstatement of ethanol-induced conditioned place preference in mice: effects of opioid receptor-like 1 receptor agonists and naloxone. J Pharmacol Exp Ther (2003) 1.25
Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice. J Pharmacol Exp Ther (2006) 1.25
A systematic review of variables associated with the relationship between obesity and depression. Obes Rev (2013) 1.24
Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system. Biol Psychiatry (2006) 1.20
Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology (2003) 1.18
Targeted disruption of the orphanin FQ/nociceptin gene increases stress susceptibility and impairs stress adaptation in mice. Proc Natl Acad Sci U S A (1999) 1.17
Effect of nociceptin on alcohol intake in alcohol-preferring rats. Psychopharmacology (Berl) (1999) 1.17
Orphanin FQ/nociceptin not only blocks but also reverses behavioral adaptive changes induced by repeated cocaine in mice. Biol Psychiatry (2010) 1.15
Orphanin FQ, agonist of orphan opioid receptor ORL1, stimulates feeding in rats. Neuroreport (1996) 1.14
Dysregulation of nociceptin/orphanin FQ activity in the amygdala is linked to excessive alcohol drinking in the rat. Biol Psychiatry (2008) 1.14
Unrestrained nociceptive response and disregulation of hearing ability in mice lacking the nociceptin/orphaninFQ receptor. EMBO J (1997) 1.13
Orphanin FQ/nociceptin attenuates motor stimulation and changes in nucleus accumbens extracellular dopamine induced by cocaine in rats. Psychopharmacology (Berl) (2001) 1.12
Effect of nociceptin/orphanin FQ on the rewarding properties of morphine. Eur J Pharmacol (2000) 1.12
Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor. Peptides (2000) 1.11
Role of innate and drug-induced dysregulation of brain stress and arousal systems in addiction: Focus on corticotropin-releasing factor, nociceptin/orphanin FQ, and orexin/hypocretin. Brain Res (2009) 1.11
The peptide orphanin FQ inhibits beta-endorphin neurons and neurosecretory cells in the hypothalamic arcuate nucleus by activating an inwardly-rectifying K+ conductance. Neuroendocrinology (1998) 1.10
Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active. Anesthesiology (2011) 1.09
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vivo studies. J Pharmacol Exp Ther (2007) 1.09
Synthesis of (1S,3aS)-8-(2,3,3a,4,5, 6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4. 5]decan-4-one, a potent and selective orphanin FQ (OFQ) receptor agonist with anxiolytic-like properties. Eur J Med Chem (2000) 1.08
Orphanin FQ/nociceptin but not Ro 65-6570 inhibits the expression of cocaine-induced conditioned place preference. Behav Pharmacol (2002) 1.08
Pharmacological characterization of the novel nonpeptide orphanin FQ/nociceptin receptor agonist Ro 64-6198: rapid and reversible desensitization of the ORL1 receptor in vitro and lack of tolerance in vivo. J Pharmacol Exp Ther (2001) 1.05
Buprenorphine: dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans. Biol Psychiatry (1993) 1.05
Nociceptin/orphanin FQ increases anxiety-related behavior and circulating levels of corticosterone during neophobic tests of anxiety. Neuropsychopharmacology (2004) 1.05
Nociceptin/orphanin FQ and opioid receptor-like receptor mRNA expression in dopamine systems. J Comp Neurol (2002) 1.04
Neuropeptide modulation of central amygdala neuroplasticity is a key mediator of alcohol dependence. Neurosci Biobehav Rev (2011) 1.04
Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications. Curr Drug Targets (2007) 1.04
Rats maintained chronically on buprenorphine show reduced heroin and cocaine seeking in tests of extinction and drug-induced reinstatement. Neuropsychopharmacology (2005) 1.04
Agonistic effect of buprenorphine in a nociceptin/OFQ receptor-triggered reporter gene assay. Mol Pharmacol (1999) 1.04
Melanocortin activation of nucleus of the solitary tract avoids anorectic tachyphylaxis and induces prolonged weight loss. Am J Physiol Endocrinol Metab (2007) 1.03
A combination of buprenorphine and naltrexone blocks compulsive cocaine intake in rodents without producing dependence. Sci Transl Med (2012) 1.01
The anxiolytic-like effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol (SCH 221510). J Pharmacol Exp Ther (2008) 1.01
High-affinity, non-peptide agonists for the ORL1 (orphanin FQ/nociceptin) receptor. J Med Chem (2000) 1.00
Nociceptin differentially affects morphine-induced dopamine release from the nucleus accumbens and nucleus caudate in rats. Peptides (2000) 0.99
Injections of nociceptin into nucleus accumbens shell or ventromedial hypothalamic nucleus increase food intake. Neuroreport (1997) 0.99
Nociceptin/orphanin FQ inhibits stress- and CRF-induced anorexia in rats. Neuroreport (2001) 0.99
Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals. Drugs (2012) 0.99
LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacology (2013) 0.99
Orphanin FQ, a novel neuropeptide with anti-stress-like activity. Brain Res (1999) 0.98
Functional heterogeneity in dopamine release and in the expression of Fos-like proteins within the rat striatal complex. Eur J Neurosci (1999) 0.98
Structures that delineate orphanin FQ and dynorphin A pharmacological selectivities. J Biol Chem (1998) 0.98
Synthesis and evaluation of radioligands for imaging brain nociceptin/orphanin FQ peptide (NOP) receptors with positron emission tomography. J Med Chem (2011) 0.98
Orphanin FQ/nociceptin blocks cocaine-induced behavioral sensitization in rats. Psychopharmacology (Berl) (2002) 0.97
Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes. Brain Res (2006) 0.96
Ligand-regulated internalization of the opioid receptor-like 1: a confocal study. Endocrinology (2004) 0.96
Nociceptin inhibits acquisition of amphetamine-induced place preference and sensitization to stereotypy in rats. Eur J Pharmacol (2003) 0.96
Activation of brain NOP receptors attenuates acute and protracted alcohol withdrawal symptoms in the rat. Alcohol Clin Exp Res (2011) 0.96
Nociceptin/orphanin FQ blockade of corticotropin-releasing factor-induced gamma-aminobutyric acid release in central amygdala is enhanced after chronic ethanol exposure. Biol Psychiatry (2011) 0.95
Depressive symptoms during buprenorphine treatment of opioid abusers. J Subst Abuse Treat (1990) 0.95
Inhibitory effect of nociceptin on [3H]-5-HT release from rat cerebral cortex slices. Br J Pharmacol (1999) 0.94
Brain and whole-body imaging of nociceptin/orphanin FQ peptide receptor in humans using the PET ligand 11C-NOP-1A. J Nucl Med (2012) 0.94
Pharmacological characterization of the nociceptin receptor mediating hyperphagia: identification of a selective antagonist. Psychopharmacology (Berl) (2000) 0.94
Nociceptin/orphanin FQ regulates neuroendocrine function of the limbic-hypothalamic-pituitary-adrenal axis. Neuroscience (2001) 0.94
Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species. Psychopharmacology (Berl) (2005) 0.94
Activation of the NPY Y5 receptor regulates both feeding and energy expenditure. Am J Physiol (1999) 0.94
Functional antagonism between nociceptin/orphanin FQ (N/OFQ) and corticotropin-releasing factor (CRF) in the rat brain: evidence for involvement of the bed nucleus of the stria terminalis. Psychopharmacology (Berl) (2007) 0.94
A non-rewarding, non-aversive buprenorphine/naltrexone combination attenuates drug-primed reinstatement to cocaine and morphine in rats in a conditioned place preference paradigm. Addict Biol (2012) 0.93
Nociceptin/orphanin FQ metabolism and bioactive metabolites. Peptides (2000) 0.93
Antidepressant- and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands. Naunyn Schmiedebergs Arch Pharmacol (2006) 0.93
The role of the NOP receptor in regulating food intake, meal pattern, and the excitability of proopiomelanocortin neurons. Neuropharmacology (2010) 0.92
Functional interaction between nociceptin/orphanin FQ and alpha-melanocyte-stimulating hormone in the regulation of feeding. Peptides (2006) 0.92
Reversal of stress- and CRF-induced anorexia in rats by the synthetic nociceptin/orphanin FQ receptor agonist, Ro 64-6198. Psychopharmacology (Berl) (2002) 0.92
Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test. Eur J Neurosci (2003) 0.92
Orexins/hypocretins: pain regulation and cellular actions. Curr Pharm Des (2010) 0.92
Nociceptin/orphanin FQ content is decreased in forebrain neurones during acute stress. J Neuroendocrinol (2003) 0.92
Nociceptin/orphanin FQ acts as a functional antagonist of corticotropin-releasing factor to inhibit its anorectic effect. Physiol Behav (2004) 0.91
Central injections of nocistatin or its C-terminal hexapeptide exert anxiogenic-like effect on behaviour of mice in the plus-maze test. Br J Pharmacol (2002) 0.91
Brain and whole-body imaging in rhesus monkeys of 11C-NOP-1A, a promising PET radioligand for nociceptin/orphanin FQ peptide receptors. J Nucl Med (2011) 0.90
Comparison of buprenorphine and methadone effects on opiate self-administration in primates. J Pharmacol Exp Ther (1983) 0.90
Different alcohol exposures induce selective alterations on the expression of dynorphin and nociceptin systems related genes in rat brain. Addict Biol (2011) 0.90
Distribution of prepro-nociceptin/orphanin FQ mRNA and its receptor mRNA in developing and adult mouse central nervous systems. J Comp Neurol (1998) 0.90
Distinct mechanisms for activation of the opioid receptor-like 1 and kappa-opioid receptors by nociceptin and dynorphin A. Mol Pharmacol (1999) 0.90